Skip NavigationSkip to Content
Return Return to Search Results

Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502)

  1. Author:
    Hariprakasha, H. K.
    Kosakowska-Cholody, T.
    Meyer, C.
    Cholody, W. M.
    Stinson, S. F.
    Tarasova, N. I.
    Michejda, C. J.

  2. Author Address

    NCI, Ctr Canc Res, Mol Aspects Drug Design Sect, Struct Biophys Lab, Frederick, MD 21702 USA. NCI, Dev Therapeut Program, Frederick, MD 21702 USA. Reata Pharmaceut, Irving, TX USA.;Tarasova, NI, NCI, Ctr Canc Res, Mol Aspects Drug Design Sect, Struct Biophys Lab, Frederick, MD 21702 USA.;tarasova@ncifcrf.gov
    1. Year: 2007
    2. Date: Nov
  2. Journal: Journal of Medicinal Chemistry
    1. 50
    2. 23
    3. Pages: 5557-5560
  4. Type of Article: Article
  5. ISSN: 0022-2623
  1. Abstract:

    Unsymmetrical bifunctional antitumor agent WMC79 was further optimized to generate compound 7b that not only inhibited the growth of many tumor cell lines, but caused rapid apoptosis. Unlike the parent compound, 7b is toxic to both p53 positive and negative cancer cells. It. has potent in vivo activity against xenografts of human colon and pancreatic tumors in athymic mice.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1021/jm7009777
  3. View record in Web of Science®
  4. WOS: 000250809300007

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel